LIGAND PHARMACEUTICAL INC (LGNXZ)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 48.62 Million | 137.85 Million | 78.79 Million | 54.58 Million | -29.33 Million | 194.05 Million |
| Net Income | 53.81 Million | -5.21 Million | 76.35 Million | -2.98 Million | 629.3 Million | 143.32 Million |
| Depreciation & Amortization | 37.41 Million | 43.39 Million | 41.33 Million | 27.96 Million | 43.73 Million | 16.69 Million |
| Deferred income taxes | 11.69 Million | 20.72 Million | -8.61 Million | -19.05 Million | 74.82 Million | 29.73 Million |
| Stock-based compensation | - | - | 38.78 Million | 30.72 Million | 24.51 Million | 20.84 Million |
| Change in working capital | -34.4 Million | 65.67 Million | -57 Million | -10.06 Million | -4.21 Million | -41.78 Million |
| Other non-cash items | 74.88 Million | 34.44 Million | 139.61 Million | 150.61 Million | -690.87 Million | 116.12 Million |
| Investing Cash Flow | -11.68 Million | 163.62 Million | 30.52 Million | 231.64 Million | 466.91 Million | -423.26 Million |
| Investments in PPE | -53.84 Million | -17.92 Million | -8.76 Million | -4.45 Million | -2.55 Million | -10.88 Million |
| Acquisitions | -10.4 Million | - | - | -404.88 Million | -11.84 Million | -5.85 Million |
| Investment purchases | -142.01 Million | -51.97 Million | -181.32 Million | -423.02 Million | -2.35 Billion | -1.43 Billion |
| Sales/Maturities of investments | 194.16 Million | 234.39 Million | 221.33 Million | 1.03 Billion | 2.03 Billion | 1.02 Billion |
| Other Investing Activities | 418 Thousand | -868 Thousand | -726 Thousand | 25.31 Million | 808.12 Million | 2.91 Million |
| Financing Cash Flow | -58.99 Million | -275.99 Million | -137.76 Million | -310.54 Million | -485.17 Million | 328.58 Million |
| Debt repayment | -76.89 Million | -260.8 Million | -146.01 Million | -231.75 Million | -14.92 Million | -814.73 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -18.44 Million | -77.99 Million | -453.42 Million | -152.96 Million |
| Common Stock Issuance | 22.44 Million | 3.23 Million | 33.76 Million | 3.01 Million | 2.99 Million | 110.18 Million |
| Other Financing Activities | -4.54 Million | -18.42 Million | -7.06 Million | -3.8 Million | -19.81 Million | -443.37 Million |
| Accounts receivables | -4.38 Million | 56.89 Million | -32.59 Million | -16.91 Million | 14.24 Million | -29.54 Million |
| Accounts payables | -4.7 Million | -3.34 Million | 2.81 Million | -1.24 Million | -6.82 Million | -4.54 Million |
| Inventory | -10.87 Million | 12.05 Million | -427 Thousand | -17.79 Million | -2.06 Million | -2.55 Million |
| Other working capital | -14.44 Million | 61 Thousand | -26.79 Million | 25.89 Million | -9.57 Million | -5.14 Million |
| Cash at beginning of period | 45 Million | 19.52 Million | 47.96 Million | 72.27 Million | 119.78 Million | 20.62 Million |
| Cash at end of period | 22.95 Million | 45 Million | 19.52 Million | 47.96 Million | 72.27 Million | 119.78 Million |
| Capital Expenditure | -53.84 Million | -17.92 Million | -8.76 Million | -4.45 Million | -2.55 Million | -10.88 Million |
| Effect of forex changes on cash | - | - | - | 300.99 Million | 485.17 Million | - |
| Net cash flow / Change in cash | -22.05 Million | 25.48 Million | -28.44 Million | -24.31 Million | -47.5 Million | 99.16 Million |
| Free Cash Flow | -5.22 Million | 119.92 Million | 70.03 Million | 50.12 Million | -31.88 Million | 183.17 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -51.91 Million | 86.13 Million | 18.18 Million | 53.81 Million | -10.27 Million | 2.29 Million |
| Depreciation & Amortization | 9.35 Million | 9.24 Million | 9.43 Million | 37.41 Million | 8.87 Million | 9.51 Million |
| Deferred income taxes | -20.66 Million | 19.54 Million | 4.93 Million | 11.69 Million | 8 Million | -10 Million |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -7.61 Million | 8.24 Million | -15.99 Million | -34.4 Million | -20.83 Million | -5.47 Million |
| Other non-cash items | 107.58 Million | -90.7 Million | 4.89 Million | 74.88 Million | 50.64 Million | 38.76 Million |
| Investing Cash Flow | -54.75 Million | -3.77 Million | -10.28 Million | -11.68 Million | -19.5 Million | 7.55 Million |
| Investments in PPE | -2.13 Million | -2.54 Million | -50.74 Million | -53.84 Million | -487 Thousand | -203 Thousand |
| Acquisitions | - | - | - | -10.4 Million | -10.4 Million | - |
| Investment purchases | -24.44 Million | -78.63 Million | -19.51 Million | -142.01 Million | -33.5 Million | -49.12 Million |
| Sales/Maturities of investments | 47.05 Million | 75.46 Million | 59.9 Million | 194.16 Million | 24.76 Million | 56.8 Million |
| Other Investing Activities | -75.23 Million | 1.94 Million | 69 Thousand | 418 Thousand | 136 Thousand | 83 Thousand |
| Financing Cash Flow | 9.54 Million | 12.22 Million | 6.26 Million | -58.99 Million | 3.27 Million | -67.75 Million |
| Debt repayment | -4000.00 | -5000.00 | -45 Thousand | -76.89 Million | - | -76.84 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 9.55 Million | 15.3 Million | 6.52 Million | 22.44 Million | 7.57 Million | 9.11 Million |
| Other Financing Activities | - | -3.07 Million | -217 Thousand | -4.54 Million | -4.3 Million | -26 Thousand |
| Accounts receivables | -9.04 Million | 3.46 Million | 1.05 Million | -4.38 Million | -7.91 Million | 1.37 Million |
| Accounts payables | 1.77 Million | -1.38 Million | 2.75 Million | -4.7 Million | -2.5 Million | -4.52 Million |
| Inventory | 2.48 Million | 2.63 Million | 707 Thousand | -10.87 Million | -611 Thousand | -13 Million |
| Other working capital | -2.82 Million | 3.53 Million | -20.5 Million | -14.44 Million | -9.8 Million | 10.67 Million |
| Cash at beginning of period | 50.09 Million | 22.95 Million | 19.27 Million | 45 Million | 28.44 Million | 88.72 Million |
| Cash at end of period | 18.13 Million | 50.09 Million | 22.95 Million | 22.95 Million | 19.27 Million | 28.44 Million |
| Capital Expenditure | -2.13 Million | -2.54 Million | -50.74 Million | -53.84 Million | -487 Thousand | -203 Thousand |
| Effect of forex changes on cash | - | - | 583 Thousand | - | -583 Thousand | -1.00 |
| Net cash flow / Change in cash | -31.95 Million | 27.13 Million | 3.67 Million | -22.05 Million | -9.17 Million | -60.28 Million |
| Free Cash Flow | 11.11 Million | 16.14 Million | -43.62 Million | -5.22 Million | 7.15 Million | -284.99 Thousand |
ZAIRF
AHELF
ACNI
BKRP
601212
POD